The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Combination Antifungal Therapy for Cryptococcal Meningitis
Open accessAbstract
BACKGROUND: Combination antifungal therapy (amphotericin B deoxycholate and flucytosine) is the recommended treatment for cryptococcal meningitis but has not been shown to reduce mortality, as compared with amphotericin B alone. We performed a randomized, controlled trial to determine whether combining flucytosine or high-dose fluconazole with high-dose amphotericin B improved survival at 14 and 70 days. METHODS: We conducted a randomized, three-group, open-label trial of induction therapy for cryptococcal meningitis in patients with human immunodeficiency virus infection. All patients received amphotericin B at a dose of 1 mg per kilogram of body weight per day; patients in group 1 were treated for 4 weeks, and those in groups 2 and 3 for 2 weeks. Patients in group 2 concurrently received flucytosine at a dose of 100 mg per kilogram per day for 2 weeks, and those in group 3 concurrently received fluconazole at a dose of 400 mg twice daily for 2 weeks. RESULTS: A total of 299 patients were enrolled. Fewer deaths occurred by days 14 and 70 among patients receiving amphotericin B and flucytosine than among those receiving amphotericin B alone (15 vs. 25 deaths by day 14; hazard ratio, 0.57; 95% confidence interval [CI], 0.30 to 1.08; unadjusted P=0.08; and 30 vs. 44 deaths by day 70; hazard ratio, 0.61; 95% CI, 0.39 to 0.97; unadjusted P=0.04). Combination therapy with fluconazole had no significant effect on survival, as compared with monotherapy (hazard ratio for death by 14 days, 0.78; 95% CI, 0.44 to 1.41; P=0.42; hazard ratio for death by 70 days, 0.71; 95% CI, 0.45 to 1.11; P=0.13). Amphotericin B plus flucytosine was associated with significantly increased rates of yeast clearance from cerebrospinal fluid (-0.42 log10 colony-forming units [CFU] per milliliter per day vs. -0.31 and -0.32 log10 CFU per milliliter per day in groups 1 and 3, respectively; P<0.001 for both comparisons). Rates of adverse events were similar in all groups, although neutropenia was more frequent in patients receiving a combination therapy. CONCLUSIONS: Amphotericin B plus flucytosine, as compared with amphotericin B alone, is associated with improved survival among patients with cryptococcal meningitis. A survival benefit of amphotericin B plus fluconazole was not found. (Funded by the Wellcome Trust and the British Infection Society; Controlled-Trials.com number, ISRCTN95123928.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mice: Multivariate Imputation by Chained Equations in R
Buuren, S. V., & Groothuis-Oudshoorn, K. (2011) · Journal of Statistical Software · doi:10.18637/jss.v045.i03 · Cited by 13,870
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Park, B. J., Wannemuehler, K. A., Marston, B. J., Govender, N., Pappas, P. G., & Chiller, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e328322ffac · Cited by 2,014
Bretz, F., Hothorn, T., & Westfall, P. (2016) · doi:10.1201/9781420010909 · Cited by 1,233
Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and Adults
Thwaites, G. E., Bang, N. D., Dung, N. H., Quy, H. T., Oanh, D. T. T., Thoa, N. T. C., Hien, N. Q., Thuc, N. T., Hai, N. N., Lan, N. T. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040573 · Cited by 1,043
Self-citationMolecular Evolution: A Phylogenetic Approach
Page, R., & Holmes, E. C. (1998) · Medical Entomology and Zoology · Cited by 979
Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome
van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D., Johnson, P. C., Tuazon, C. U., Kerkering, T., Moskovitz, B. L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707033370103 · Cited by 820
Infections with Cryptococcus neoformans in the Acquired Immunodeficiency Syndrome
Chuck, S. L., & Sande, M. A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909213211205 · Cited by 797
Dexamethasone for treatment of tuberculous meningitis in adolescents and adults
Tunkel, A. R. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0059-0 · Cited by 671
Saag, M. S., Powderly, W. G., Cloud, G. A., Robinson, P., Grieco, M. H., Sharkey, P. K., Thompson, S. E., Sugar, A. M., Tuazon, C. U., Fisher, J. F., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260202 · Cited by 631
Graybill, J. R., Sobel, J., Saag, M., van der Horst, C., Powderly, W., Cloud, G., Riser, L., Hamill, R., Dismukes, W., & NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups (2000) · Clinical Infectious Diseases · doi:10.1086/313603 · Cited by 486
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
Brouwer, A. E., Rajanuwong, A., Chierakul, W., Griffin, G. E., Larsen, R. A., White, N. J., & Harrison, T. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16301-0 · Cited by 470
Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study
Dromer, F., Mathoulin-Pélissier, S., Launay, O., Lortholary, O., & the French Cryptococcosis Study Group (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040021 · Cited by 374
Multiplicity in randomised trials I: endpoints and treatments
Schulz, K. F., & Grimes, D. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66461-6 · Cited by 366
Saag, M. S., Cloud, G. A., Graybill, J. R., Sobel, J. D., Tuazon, C. U., Johnson, P. C., Fessel, W. J., Moskovitz, B. L., Wiesinger, B., Cosmatos, D., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515110 · Cited by 244
Clinical Epidemiological Study of 171 Cases of Cryptococcosis
Rozenbaum, R., & Goncalves, A. J. R. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.3.369 · Cited by 241
Bicanic, T., Wood, R., Meintjes, G., Rebe, K., Brouwer, A., Loyse, A., Bekker, L., Jaffar, S., & Harrison, T. (2008) · Clinical Infectious Diseases · doi:10.1086/588792 · Cited by 232
Bicanic, T., Muzoora, C., Brouwer, A. E., Meintjes, G., Longley, N., Taseera, K., Rebe, K., Loyse, A., Jarvis, J., Bekker, L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/604716 · Cited by 227
Practical Guidelines for Multiplicity Adjustment in Clinical Trials
Proschan, M. A., & Waclawiw, M. A. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00106-9 · Cited by 225
Longley, N., Muzoora, C., Taseera, K., Mwesigye, J., Rwebembera, J., Chakera, A., Wall, E., Andia, I., Jaffar, S., & Harrison, T. S. (2008) · Clinical Infectious Diseases · doi:10.1086/593194 · Cited by 202
Pappas, P. G., Chetchotisakd, P., Larsen, R. A., Manosuthi, W., Morris, M. I., Anekthananon, T., D, S. S. M., Supparatpinyo, K., Nolen, T. L., Zimmer, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/599112 · Cited by 154
Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis
Dromer, F., Bernède‐Bauduin, C., Guillemot, D., Lortholary, O., & for the French Cryptococcosis Study Group (2008) · PLoS ONE · doi:10.1371/journal.pone.0002870 · Cited by 144
Loyse, A., Wilson, D., Meintjes, G., Jarvis, J. N., Bicanic, T. A., Bishop, L., Rebe, K. B., Williams, A., Jaffar, S. S., Bekker, L., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir745 · Cited by 134
Molecular Evolution — A Phylogenetic Approach.
Tristem, M. (2000) · Heredity · doi:10.1046/j.1365-2540.2000.0696a.x · Cited by 87
Pitisuttithum, P., Tansuphasawadikul, S., Simpson, A. J. H., Howe, P. A., & White, N. J. (2001) · Journal of Infection · doi:10.1053/jinf.2001.0916 · Cited by 73
Sloan, D. J., Dlamini, S. K., Paul, N., et al. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005647.pub2 · Cited by 61
Cited by
Maziarz, E. K., & Perfect, J. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.006 · Cited by 698
Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593
Cryptococcus: from environmental saprophyte to global pathogen
May, R. C., Stone, N. R. H., Wiesner, D. L., Bicanic, T., & Nielsen, K. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2015.6 · Cited by 541
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
Boulware, D. R., Meya, D. B., Muzoora, C., Rolfes, M. A., Huppler Hullsiek, K., Musubire, A., Taseera, K., Nabeta, H. W., Schutz, C., Williams, D. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312884 · Cited by 497
Metadata
- Authors
- Day, J. N., Chau, T. T. H., Wolbers, M., Mai, P. P., Dung, N. T., Mai, N. H., Phu, N. H., Nghia, H. D., Phong, N. D., Thai, C. Q., Thai, L. H., Chuong, L. V., Sinh, D. X., Duong, V. A., Hoang, T. N., Diep, P. T., Campbell, J. I., Sieu, T. P. M., Baker, S. G., Chau, N. V. V., Hien, T. T., Lalloo, D. G., & Farrar, J. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-04-04
- Volume
- 368
- Issue
- 14
- Pages
- 1291-1302
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096006098
- Cited by
- 545
- References
- 26
- FWCI
- 39.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.